Timber Hill LLC Buys Shares of 18,031 Amgen, Inc. (AMGN)

Timber Hill LLC bought a new stake in shares of Amgen, Inc. (NASDAQ:AMGN) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 18,031 shares of the medical research company’s stock, valued at approximately $3,136,000.

Other large investors have also bought and sold shares of the company. South Texas Money Management Ltd. boosted its stake in shares of Amgen by 0.7% during the 2nd quarter. South Texas Money Management Ltd. now owns 3,223 shares of the medical research company’s stock worth $555,000 after purchasing an additional 22 shares during the last quarter. Glenview Trust Co boosted its stake in shares of Amgen by 0.4% during the 2nd quarter. Glenview Trust Co now owns 6,137 shares of the medical research company’s stock worth $1,057,000 after purchasing an additional 25 shares during the last quarter. Roberts Glore & Co. Inc. IL boosted its stake in shares of Amgen by 0.4% during the 2nd quarter. Roberts Glore & Co. Inc. IL now owns 7,425 shares of the medical research company’s stock worth $1,279,000 after purchasing an additional 27 shares during the last quarter. Salem Investment Counselors Inc. boosted its stake in shares of Amgen by 4.7% during the 2nd quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock worth $139,000 after purchasing an additional 36 shares during the last quarter. Finally, Keel Point LLC boosted its stake in shares of Amgen by 1.2% during the 2nd quarter. Keel Point LLC now owns 3,509 shares of the medical research company’s stock worth $604,000 after purchasing an additional 43 shares during the last quarter. Hedge funds and other institutional investors own 79.53% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several equities research analysts have issued reports on AMGN shares. Oppenheimer reaffirmed a “buy” rating and set a $205.00 price target on shares of Amgen in a research note on Tuesday, January 30th. Argus raised shares of Amgen from a “hold” rating to a “buy” rating and raised their price target for the stock from $192.33 to $220.00 in a research note on Tuesday, January 23rd. Piper Jaffray reaffirmed a “buy” rating on shares of Amgen in a research note on Tuesday, January 2nd. Mizuho set a $192.00 price target on shares of Amgen and gave the stock a “buy” rating in a research note on Thursday, December 28th. Finally, Goldman Sachs cut shares of Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the stock. Amgen currently has a consensus rating of “Hold” and an average target price of $190.57.

Shares of AMGN stock opened at $168.14 on Friday. The company has a market cap of $123,936.70, a price-to-earnings ratio of 13.67, a price-to-earnings-growth ratio of 2.11 and a beta of 1.36. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49. Amgen, Inc. has a fifty-two week low of $152.16 and a fifty-two week high of $201.23.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The company’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period last year, the firm earned $2.89 earnings per share. equities research analysts anticipate that Amgen, Inc. will post 13.25 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be given a dividend of $1.32 per share. The ex-dividend date is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a yield of 3.14%. Amgen’s dividend payout ratio (DPR) is 41.97%.

Amgen declared that its Board of Directors has authorized a share repurchase plan on Thursday, February 1st that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total transaction of $283,070.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 4,575 shares of company stock worth $838,064. 0.19% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Timber Hill LLC Buys Shares of 18,031 Amgen, Inc. (AMGN)” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3337851/timber-hill-llc-buys-shares-of-18031-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Perrigo  Given a $105.00 Price Target by Canaccord Genuity Analysts
Perrigo Given a $105.00 Price Target by Canaccord Genuity Analysts
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Proteostasis Therapeutics  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Proteostasis Therapeutics Stock Price
FTD Companies  Getting Somewhat Positive Press Coverage, Report Shows
FTD Companies Getting Somewhat Positive Press Coverage, Report Shows
Koovs  Stock Price Up 28.2%
Koovs Stock Price Up 28.2%
Rigel Pharmaceuticals   Shares Down 6.5%
Rigel Pharmaceuticals Shares Down 6.5%
Dicerna Pharmaceuticals  Shares Up -6.6%
Dicerna Pharmaceuticals Shares Up -6.6%


© 2006-2018 Ticker Report. Google+.